DexCom Inc (DXCM)vsIntelligent Bio Solutions Inc. (INBS)
DXCM
DexCom Inc
$75.69
-1.25%
HEALTHCARE · Cap: $29.58B
INBS
Intelligent Bio Solutions Inc.
$1.97
-6.68%
HEALTHCARE · Cap: $5.50M
Smart Verdict
WallStSmart Research — data-driven comparison
DexCom Inc generates 123016% more annual revenue ($4.82B vs $3.91M). DXCM leads profitability with a 19.3% profit margin vs -296.8%. DXCM earns a higher WallStSmart Score of 72/100 (B).
DXCM
Strong Buy72
out of 100
Grade: B
INBS
Hold38
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+89.7%
Fair Value
$659.33
Current Price
$75.69
$583.64 discount
Margin of Safety
-26.5%
Fair Value
$4.15
Current Price
$1.97
$2.18 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 31 in profit
Earnings expanding 92.2% YoY
Strong operational efficiency at 21.4%
15.0% revenue growth
Reasonable price relative to book value
Revenue surging 45.5% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Trading at 9.9x book value
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -170.2% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : DXCM
The strongest argument for DXCM centers on Return on Equity, EPS Growth, Operating Margin. Profitability is solid with margins at 19.3% and operating margin at 21.4%. Revenue growth of 15.0% demonstrates continued momentum.
Bull Case : INBS
The strongest argument for INBS centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 45.5% demonstrates continued momentum.
Bear Case : DXCM
The primary concerns for DXCM are P/E Ratio, Price/Book.
Bear Case : INBS
The primary concerns for INBS are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
DXCM profiles as a mature stock while INBS is a hypergrowth play — different risk/reward profiles.
INBS carries more volatility with a beta of 4.17 — expect wider price swings.
INBS is growing revenue faster at 45.5% — sustainability is the question.
DXCM generates stronger free cash flow (449M), providing more financial flexibility.
Bottom Line
DXCM scores higher overall (72/100 vs 38/100), backed by strong 19.3% margins and 15.0% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
DexCom Inc
HEALTHCARE · MEDICAL DEVICES · USA
DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.
Intelligent Bio Solutions Inc.
HEALTHCARE · MEDICAL DEVICES · USA
Intelligent Bio Solutions Inc. (INBS) is a cutting-edge biotechnology company focused on pioneering advanced diagnostic solutions and biomarker-driven technologies specifically designed for drug abuse testing and monitoring. By leveraging innovative scientific methodologies, INBS provides rapid and precise testing options that facilitate timely clinical decision-making and enhance patient outcomes. As the healthcare landscape increasingly demands sophisticated diagnostic tools, INBS is well-positioned to spearhead advancements in healthcare diagnostics, reaffirming its dedication to elevating healthcare quality and operational efficiency.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?